We canβt show the full text here under this license. Use the link below to read it at the source.
Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis
Glucagon-like peptide-1 treatments and their effects on weight and blood sugar in people with type 2 diabetes and obesity
AI simplified
Abstract
GLP-1 receptor agonists reduced body mass index by approximately 1.02 kg in patients with type 2 diabetes over 24 months.
- GLP-1 receptor agonists also significantly decreased fasting plasma glucose levels by an average of -21.34 mg/dL.
- A reduction in hemoglobin A1c levels of -0.58% was observed with GLP-1 receptor agonists compared to other treatments.
- The study included 1000 patients with type 2 diabetes, of which 220 received GLP-1 receptor agonists.
- The findings suggest that GLP-1 receptor agonists may be more effective than other second-line diabetes treatments for reducing BMI and blood glucose levels.
AI simplified
Key numbers
1.02 kg/mΒ²
Reduction
Average treatment effect of compared to other second-line treatments.
21.34 mg/dL
FPG Reduction
Average treatment effect on levels.
0.56%
Reduction
Average treatment effect on levels.